Drug

Enalapril

Approved · EMA

Emerging researchLate-stage development

Also known as (S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline, 1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester, Enalapril-Hydrochlorothiazide, Epaned+8 more

(S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline, 1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester, Enalapril-Hydrochlorothiazide, Epaned, Lexxel, Teczem, Vaseretic, Vasotec, ánalapril, Enalaprila, Enalapril Maleate, Enalaprilum.

RxNorm3827 ChEMBLCHEMBL578 ATCC09AA02UNII69PN84IO1A

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy. The Study is Also Know as Prevention And Reduction of Adverse Outcomes in Chagasic Heart failUre Trial Evaluation (PARACHUTE-HF).

Clinical trial2026-05-11Results posted · ClinicalTrials.gov

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Clinical trial2026-05-08Results expected Q1 2029 · ClinicalTrials.gov

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Clinical trial2026-05-06Results expected Q2 2028 · ClinicalTrials.gov

Genetic Determinants of ACEI Prodrug Activation

Clinical trial2026-01-01Completed · ClinicalTrials.gov

Cardiovascular Protection After Preeclampsia With Enalapril

Clinical trial2025-10-30Results expected Q4 2027 · ClinicalTrials.gov

Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy

Clinical trial2025-06-22Results expected Q4 2029 · ClinicalTrials.gov

A Single Center, Single Arm, Phase 2, Pilot Study to Investigate the Efficacy of the ACE Inhibitor Enalapril in Participants Aged 18-70 Years of Age With Painful Venous Malformations.

Clinical trial2025-04-02Results expected Q4 2029 · ClinicalTrials.gov

Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction - PRESENT HF Study

Clinical trial2025-02-01Primary completion · ClinicalTrials.gov

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: Randomized Trial ANSWER-HF

Clinical trial2024-12-01Primary completion · ClinicalTrials.gov

A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension

Clinical trial2024-05-23Results posted · ClinicalTrials.gov

Approval: Aqumeldi (EMA)

Regulatory2023-11-15EMA

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Research2014-08-30The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Enalapril

Aliases & brands

(S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl esterEnalapril-HydrochlorothiazideEpanedLexxelTeczemVasereticVasotecánalaprilEnalaprilaEnalapril MaleateEnalaprilum

RxNorm CUI

3827

ChEMBL ID

CHEMBL578

ATC codes

C09AA02

UNII

69PN84IO1A

Regulatory jurisdictions

ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2023-11-15

Latest approval

2023-11-15

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2023-11-15Approval

Approval: Aqumeldi (EMA)

Indication: Treatment of heart failure.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

79 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 79

Early Phase 11Phase 15Phase 1 / 21Phase 212Phase 2 / 33Phase 324Phase 425Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Not yet recruitingPH IVBaylor Research Instituten=642029

Genetic Determinants of ACEI Prodrug Activation

CompletedPH IVUniversity of Michigann=212026

Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction - PRESENT HF Study

Unknown statusPH IVClinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznańn=2602025

CompletedPH IVNovartis Pharmaceuticalsn=9222025

Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks

CompletedPH IVYang I. Pachankisn=12023

Recent completions

Trials that read out recently, adding to the completed evidence base.

Genetic Determinants of ACEI Prodrug Activation

CompletedPH IVUniversity of Michigann=212026

CompletedPH IVNovartis Pharmaceuticalsn=9222025

Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: a Phase 3 Randomised, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced CardioToxicity

CompletedPH IIISouth Tees Hospitals NHS Foundation Trustn=1112023

Blood Pressure Management in Stroke Following Endovascular Treatment

CompletedPH IIHamilton Health Sciences Corporationn=302023

Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks

CompletedPH IVYang I. Pachankisn=12023

Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCZ696 Followed by a 52-week Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared With Enalapril in Pediatric Patients From 1 Month to < 18 Years of Age With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction

CompletedPH II/IIINovartis Pharmaceuticalsn=3932022

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

The New England journal of medicine · 2014 · 4,715 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Valsartan

Studied across the same disease area as Enalapril in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.